Roberta Agabio1, Antonio Preti, Gian Luigi Gessa. 1. Department of Biomedical Sciences, Section of Neuroscience, Clinical Pharmacology, University of Cagliari, Cagliari, Italy.
Abstract
BACKGROUND: It has been reported that baclofen, a drug used in the treatment of spasticity, reduces the severity of withdrawal symptoms and substance use disorders (SUDs) for some psychoactive drugs. AIMS AND METHODS: To evaluate the effectiveness and safety of baclofen in the treatment of withdrawal syndrome and/or SUDs, providing (1) an outline of its pharmacological features; (2) a summary of studies that have suggested its possible effectiveness in the treatment of SUDs, and (3) a review of randomized, controlled trials (RCTs) on baclofen and SUDs. RESULTS: Baclofen tolerability is generally considered to be good. Eleven RCTs investigated its effectiveness in the treatment of SUDs. Of these, 5 RCTs found that baclofen is effective, 5 RCTs found that it is ineffective and the results of 1 RCT were not appreciable because it did not achieve the preplanned level of participation. CONCLUSIONS: The number of RCTs on baclofen and SUDs is still low, and their results are divergent. Further RCTs should be undertaken, particularly with higher doses of baclofen. Its administration may be suggested in patients who fail to respond to other approved drugs or who are affected by liver disease that prevents their administration, or in patients affected by SUDs for which no approved drugs are available. Treatment should be conducted under strict medical supervision.
BACKGROUND: It has been reported that baclofen, a drug used in the treatment of spasticity, reduces the severity of withdrawal symptoms and substance use disorders (SUDs) for some psychoactive drugs. AIMS AND METHODS: To evaluate the effectiveness and safety of baclofen in the treatment of withdrawal syndrome and/or SUDs, providing (1) an outline of its pharmacological features; (2) a summary of studies that have suggested its possible effectiveness in the treatment of SUDs, and (3) a review of randomized, controlled trials (RCTs) on baclofen and SUDs. RESULTS:Baclofen tolerability is generally considered to be good. Eleven RCTs investigated its effectiveness in the treatment of SUDs. Of these, 5 RCTs found that baclofen is effective, 5 RCTs found that it is ineffective and the results of 1 RCT were not appreciable because it did not achieve the preplanned level of participation. CONCLUSIONS: The number of RCTs on baclofen and SUDs is still low, and their results are divergent. Further RCTs should be undertaken, particularly with higher doses of baclofen. Its administration may be suggested in patients who fail to respond to other approved drugs or who are affected by liver disease that prevents their administration, or in patients affected by SUDs for which no approved drugs are available. Treatment should be conducted under strict medical supervision.
Authors: Bradley M T Keegan; Thomas J R Beveridge; Jeffrey J Pezor; Ruoyu Xiao; Tammy Sexton; Steven R Childers; Allyn C Howlett Journal: Neuropharmacology Date: 2015-02-25 Impact factor: 5.250
Authors: Paola Maccioni; Daniela Vargiolu; Andrew W Thomas; Pari Malherbe; Claudia Mugnaini; Federico Corelli; Kimberly A Leite-Morris; Gian Luigi Gessa; Giancarlo Colombo Journal: Psychopharmacology (Berl) Date: 2014-11-26 Impact factor: 4.530
Authors: L M Paterson; D Barker; S Cro; P Mozgunov; R Phillips; C Smith; L Nahar; S Paterson; A R Lingford-Hughes Journal: Trials Date: 2022-10-18 Impact factor: 2.728
Authors: Oliver G Bosch; Fabrizio Esposito; Michael M Havranek; Dario Dornbierer; Robin von Rotz; Philipp Staempfli; Boris B Quednow; Erich Seifritz Journal: Neuropsychopharmacology Date: 2017-05-31 Impact factor: 7.853